Figure 5.

Separated peaks of E-FOL-treated cells analyzed by inhibitor sensitivity and immunoprecipitation. A, Peak fractions were analyzed by in-solution kinase assay in the presence of the inhibitors olomoucine, bohemine, roscovitine, or staurosporine and without inhibitor. The activity was quantified and is depicted as percentage of the activity without addition of inhibitor. sd of three experiments is depicted. B, Peak fractions were used for immunoprecipitation with the antibodies against the alfalfa MAP kinases SIMK (1), MMK2 (2), MMK3 (3), or SAMK (4) and subsequent in-solution kinase assay.